Development and Evaluation of Nano-based Ocular Drug Delivery System for Glaucoma
Main Article Content
Keywords
Brinzolamide, Soya phosphotidyl choline, Boric acid, and Purified Water
Abstract
Brinzolamide (BZ) is an intraocular pressure-reducing agent with low solubility. The purpose of the present study was designed to increase the Brinzolamide bioavailability by Nano micellar formulation (NMs) as an ocular drug delivery system to increase the therapeutic efficacy. Brinzolamide Nano micellar were prepared by the solvent evaporation method by using a Rota evaporator. Based on initial release studies, different formulations were prepared in various ratios of Soya phosphatidylcholine, Polysorbate 80, and Sodium glycocholate. The prepared preparation was characterized by further physicochemical investigations such as drop size, Assay, pH, osmolality, Zeta potential, and viscosity. Brinzolamide micellar formulation (Trial-5) with suitable physicochemical properties exhibited high formulation stability under different conditions. These formulations included those with a low Drop Size of 28.8 µl, Osmolality 311 mOsmol/kg, Zeta potential -0.837 mV, pH 7.2 Drug content estimation (Assay) 101.9%, and stability for at least 6 months at 25 °C/40% RH and 40 °C/25% RH. The Brinzolamide ophthalmic without preservative solution was packed in a preservative-free container by using the Novelia packing system which enhanced the stability of the preparation throughout the in-use shelf life of the solution. Finally, it was concluded that Brinzolamide NMs without preservatives packed in the Novelia packing system will be an effective package model for the Brinzolamide ophthalmic solution.
References
Nanobiotechnol 2019 Jul; 13(5): 464–470.
2. Luigi Battaglia, Loredana Serpe, Application of lipid nanoparticles to ocular drug delivery Expert Opin Drug Delivery 2016 Dec;13(12):1743-
1757.
3. Kishore Cholkar, Hoang M. Trinh. Discovery of novel inhibitors for the treatment of glaucoma. Expert Opinion Drug Discovery. 2015 March;
10(3): 293–313.
4. Kaarniranta K, Ropo A. Preferences and ease of use of preservative-free IOP-lowering eye drop containers: a comparison of two multi-dose
bottles. Clin Invest (Lond). 2018; 8:1.
5. Hong J, Bielory L. Allergy to ophthalmic preservatives. Current opinion in allergy and clinical immunology. 2009 Oct 1;9(5):447-53.
6. Pisella PJ, Fillacier K, Elena PP, Debbasch C, Baudouin C. Comparison of the effects of preserved and unpreserved formulations of
timolol on the ocular surface of albino rabbits. Ophthalmic research. 2000;32(1):3-8
7. Ishibashi T, Yokoi N, Kinoshita S. Comparison of the short-term effects on the human corneal surface of topical timolol maleate with and
without benzalkonium chloride. Journal of glaucoma. 2003 Dec 1;12(6):486-90.
8. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology.
1992 Jun 1;99(6):873-8.
9. Vishnuvardhan C, Swain D, Borkar R, Gananadhamu S, Srinivas R, Satheesh Kumar N. Study of Forced Degradation Behaviour of
Brinzolamide Using LC–ESI–Q-TOF and In Silico Toxicity Prediction. Chromatographia. 2016 Oct 1;79(19–20):1293–308.
10. Khatun R, Ashraful Islam S. Development and validation of analytical method for simultaneous estimation of Brinzolamide and Timolol by
HPLC from ophthalmic preparation. International Journal of Pharmaceutical Sciences and Research [Internet]. 2014;5(3):1001–7.
11. Shaaban Eissa M, Mamdouh Nour I, Refaat Elghobashy M, Abdelaty Shehata M. validated spectrophotometric methods for simultaneous
determination of Brinzolamide and Timolol maleate in their pure form and ophthalmic preparation by. Vol. 54, J. Pharm Sci. 2016.
12. Safwat MA, Mansour HF, Hussein AK, Abdelwahab S, Soliman GM. Polymeric micelles for the ocular delivery of triamcinolone
acetonide: preparation and in vivo evaluation in a rabbit ocular inflammatory model. Drug Delivery. 2020 Jan 1;27(1):1115–24.
13. Durgun ME, Güngör S, Özsoy Y. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases. Vol. 36, Journal of
Ocular Pharmacology and Therapeutics. Mary Ann Liebert Inc.; 2020. p. 323–41.
14. Guo C, Zhang Y, Yang Z, Li M, Li F, Cui F, et al. Nanomicelle formulation for topical delivery of cyclosporine A into the cornea: In vitro
mechanism and in vivo permeation evaluation. Scientific Reports. 2015 Aug 26;5.
15. Luschmann C, Herrmann W, Strauß O, Luschmann K, Goepferich A. Ocular delivery systems for poorly soluble drugs: An in-vivo
evaluation. International Journal of Pharmaceutics. 2013;455(1–2):331–7.
16. Di Tommaso C, Bourges JL, Valamanesh F, Trubitsyn G, Torriglia A, Jeanny JC, et al. Novel micelle carriers for cyclosporin A topical ocular
delivery: In vivo cornea penetration, ocular distribution and efficacy studies. European Journal of Pharmaceutics and Biopharmaceutics.
2012 Jun;81(2):257–64.
17. Mondon K, Zeisser-Laboube M, Gurny R, Möller M. Novel Cyclosporin A formulations using MPEG-hexyl-substituted polylactide micelles: A
suitability study. European Journal of Pharmaceutics and Biopharmaceutics. 2011 Jan;77(1):56–65.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.